Meeting
2021 Gastrointestinal Cancers Symposium
Zanidatamab (ZW25) in HER2-positive biliary tract cancers (BTCs): Results from a phase I study.
Authors
Funda Meric-Bernstam
The University of Texas MD Anderson Cancer Center, Houston, TX
Funda Meric-Bernstam , Diana L. Hanna , Anthony B. El-Khoueiry , Yoon-Koo Kang , Do-Youn Oh , Jorge M Chaves , Sun Young Rha , Erika P. Hamilton , Shubham Pant , Milind M. Javle , Kanwal Pratap Singh Raghav , Allison Fortenberry , Todd Gray , Joseph Woolery , Keun Wook Lee
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Hepatobiliary Cancer
Track
Hepatobiliary Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT02892123
Citation
J Clin Oncol 39, 2021 (suppl 3; abstr 299)
DOI
10.1200/JCO.2021.39.3_suppl.299
Abstract #
299
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2021 Gastrointestinal Cancers Symposium
A phase IIb, open-label, single-arm study of zanidatamab (ZW25) monotherapy in subjects with advanced or metastatic HER2-amplified biliary tract cancers.
First Author: Shubham Pant
Poster
2024 ASCO Annual Meeting
Zanidatamab in previously-treated HER2-positive (HER2+) biliary tract cancer (BTC): Overall survival (OS) and longer follow-up from the phase 2b HERIZON-BTC-01 study.
First Author: Shubham Pant
Poster
2018 Gastrointestinal Cancers Symposium
Preclinical study of antitumor activity of trastuzumab emtansine in HER2-positive biliary tract cancer.
First Author: Yoriko Yamashita-Kashima
Poster
2017 Gastrointestinal Cancers Symposium
Phase 1 study of ZW25, a bispecific anti-HER2 antibody, in patients with advanced HER2-expressing cancers.
First Author: Diana Felice Hausman